Australia Grants Support for TB Alliance to Advance New TB Drugs
TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB),
Press Releases
News
The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard
Global Phase 3 “STAND” Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment
* STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America
News
TB Alliance Advances Next-generation TB Drug Candidate into Clinical Testing
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354.
News
Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824)
A promising new tuberculosis (TB) drug regimen, which could improve the treatment of drug sensitive TB and multi-drug resistant (MDR-)
News
TB Alliance Announces Two New Members to Its Board of Directors: Dr. Mario Raviglione of WHO and Shalini Sharp of Ultragenyx
TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario
News
Developing New Tuberculosis Drugs from Marine Natural Products: Joint research program between OPBIO and TB Alliance announced
OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance).
News
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients
TB Alliance has launched a Phase 2B trial that will test the safety and effectiveness of a novel regimen with
News
PA-824 has a New Generic Name: Pretomanid
TB Alliance announced today that pretomanid (pronounced: pree TOH mah nid) will be the generic, nonproprietary name for its novel
News
Results of Phase 3 Clinical Trial of New Tuberculosis Drug Regimen Published in New England Journal of Medicine
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of